Hyaluronidase Effect on Infusion Set Life

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study examines the effect of hyaluronidase on the length of time of insulin infusion set wear. The aim of the study is to improve the length of time that an infusion set can be worn by infusing hyaluronidase directly into the insulin infusion site.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990

Type 1 Diabetes Mellitus

COMPLETED PHASE4

Safety and Efficacy of 7-day Wear Infusion Set vs. Control Infusion Set.

NCT04208282

Type1diabetes

COMPLETED NA

Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set

NCT02687256

Type 1 Diabetes

COMPLETED PHASE1

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934

Type 1 Diabetes Type 2 Diabetes

TERMINATED PHASE4

Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

NCT04284033

Type 1 Diabetes

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators would like to see if the use of hyaluronidase will improve insulin infusion set survival and improve the onset of insulin action. The investigators will also assess the accuracy of the Dexcom G4P sensors with extended site use beyond the 7 day FDA approved time frame.

The use of sensor information combined with the knowledge of infused insulin from pump therapy could potentially help us detect when an infusion set is beginning to fail. Information from the sensor function to the point of failure, and sensor function in response to Tylenol may allow us to develop special formulas to determine when a sensor is not working well. This will be very important for creating an artificial pancreas.

Thirty subjects will be enrolled. Fifteen patients from each of the two sites: Stanford University and University of Colorado.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyaluronidase, Then Control

Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.

On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

On weeks 2 and 4 (control weeks) no Hyaluronidase was administered.

Group Type EXPERIMENTAL

Hyaluronidase

Intervention Type DRUG

150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Control

Intervention Type OTHER

No hyaluronidase administered into insulin infusion set.

Control, Then Hyaluronidase

Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.

On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.

On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Group Type EXPERIMENTAL

Hyaluronidase

Intervention Type DRUG

150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Control

Intervention Type OTHER

No hyaluronidase administered into insulin infusion set.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronidase

150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.

Intervention Type DRUG

Control

No hyaluronidase administered into insulin infusion set.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hylenex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 3 months
2. Total daily insulin dose of at least 0.4 units/kg/day
3. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
4. Age 12 to 45 years
5. Hemoglobin A1c level less than or equal to 10%
6. Willingness to infuse 1 ml of hyaluronidase (Hylenex) into the insulin infusion set after insertion on day 1 and day 3 of the week they are assigned to use hyaluronidase
7. Willingness to use a Silhouette or Comfort insulin infusion set throughout the study. The set includes the Duo Infusion Tubing for infusion of hyaluronidase (Hylenex).
8. Willingness to eat the same breakfast each morning for the first two weeks of the study
9. Willing to take two 500mg tablets of Tylenol Regular Strength and monitor glucose levels at ½, 1, 2, 4, 6, and 8 hours later.
10. For females, not currently known to be pregnant
11. An understanding of and willingness to follow the protocol and sign the informed consent
12. Must be able to understand spoken or written English

Exclusion Criteria

1. Diabetic ketoacidosis in the past 6 months
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment
3. Known tape allergies
4. Current treatment for a seizure disorder
5. Cystic fibrosis
6. Active infection
7. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
8. Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
9. Presence of a known adrenal disorder
10. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
11. Abuse of alcohol
12. Use of an OmniPod insulin infusion pump
13. Pregnant or lactating females

Minimum Eligible Age

12 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No